Mallon Mark 4
4 · IRONWOOD PHARMACEUTICALS INC · Filed Mar 2, 2021
Insider Transaction Report
Form 4
Mallon Mark
DirectorChief Executive Officer
Transactions
- Sale
Class A Common Stock
2021-02-26$9.11/sh−22,582$205,722→ 470,605 total - Sale
Class A Common Stock
2021-02-26$9.11/sh−8,093$73,727→ 493,187 total
Footnotes (2)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.